The Patent Finder
EL

Eli Lilly and Company

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

599 patents currently held

51 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
4 more records may belong here and await a decision; they are not counted.

The next term ends in Dec 2026. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
47
Ending by 2030
Dec 2026
Next term end
440
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
GIP/GLP1 Agonist Compositions US 11,357,820
Cited by 19 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2039.
Ends Jun 2039 · High confidence
Also notable
Dose Detection for a Medication Delivery Device US 11,541,186
Cited by 14 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2039.
Ends Aug 2039 · High confidence
Also notable
Fusion Proteins and Methods of Use US 10,709,766
Cited by 40 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2036.
Ends Aug 2036 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 6 fees due Dec 2 to 30, 2026 · next Dec 2
  • 6 fees due Jan 7 to 30, 2027 · next Jan 7
  • 5 fees due Feb 6 to 22, 2027 · next Feb 6
  • 7 fees due Mar 1 to 29, 2027 · next Mar 1
  • 10 fees due Apr 1 to 22, 2027 · next Apr 1
  • 11 fees due May 5 to 28, 2027 · next May 5
  • 10 fees due Jun 3 to 30, 2027 · next Jun 3
  • 10 fees due Jul 2 to 30, 2027 · next Jul 2
  • 9 fees due Aug 6 to 23, 2027 · next Aug 6
  • 14 fees due Sep 3 to 30, 2027 · next Sep 3
  • 9 fees due Oct 7 to 30, 2027 · next Oct 7
  • 4 fees due Nov 3 to 12, 2027 · next Nov 3

Which patents, and when each one lapses · Pro

Recent changes

What they patent

The largest of its 440 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Display Screen with a Graphical User Interface5 in forceto Sep 2040
Dose Detection for a Medication Delivery Device5 in forceto Jul 2040
GIP/GLP1 Agonist Compositions5 in forceto Jun 2039
Label4 in forceto Feb 2041
Medication Delivery Device with Sensing System4 in forceto Sep 2039

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 8,110,191ANTI-IL-17 Antibodies
In force
 · High confidence
In forceHigh confidence
US 7,696,248Glucagon Receptor Antagonists, Preparation and Therapeutic Uses
In force
 · High confidence
In forceHigh confidence
US 8,084,420Rapid Acting and Long Acting Insulin Combination Formulations
In force
 · Medium confidence
In forceMedium confidence
US 7,718,609Rapid Acting and Long Acting Insulin Combination Formulations
In force
 · Medium confidence
In forceMedium confidence
US 7,968,587Tetrahydrocyclopenta[b] Indole Compounds as Androgen Receptor Modulators
In force
 · High confidence
In forceHigh confidence
US 9,708,291Novel Intermediate and Process Useful in the Preparation of {2-[1-(3,5-BIS-TRIFLUOROMETHYL-BENZYL)-5-Pyridin-4-YL-1H-[1,2,3]TRIAZOL-4-YL]-PYRIDIN-3-YL}-(2-Chlorophenyl)-METHANONE
In force
 · High confidence
In forceHigh confidence
US 10,035,787Novel Intermediate and Process Useful in the Preparation of {2-[1-(3,5-BIS-TRIFLUOROMETHYL-BENZYL)-5-Pyridin-4-YL-1H-[1,2,3]TRIAZOL-4-YL]-PYRIDIN-3-YL}-(2-Chlorophenyl)-METHANONE
In force
 · High confidence
In forceHigh confidence
US 7,452,966GLP-1 Analog Fusion Proteins
In force
 · Medium confidence
In forceMedium confidence
US 7,918,824Needled Pharmaceutical Delivery Device with Triggered Automatic Needle Insertion and Manually Controlled Pharmaceutical Injection
In force
 · High confidence
In forceHigh confidence
US 8,409,138Delay Mechanism for Automatic Injection Device
In force
 · High confidence
In forceHigh confidence
10 of 599 patents shown.
Pro members see all 599.
Pro members: see all 599 patents
Also on record, not counted in the 599: 51 patents in force now held by others · 610 patents ended · 389 applications pending · 416 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited